|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 1
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). Multicancer early detection (MCED) is an emerging form of blood-based testing that utilizes cancer biomarkers in the blood to screen for multiple cancers simultaneously (ACS, 2024). Currently, numerous clinical trials are investiga... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States (ACS, 2024; Pinsky & Berg, 2012; USPSTF, 2024). Multicancer early detection (MCED) is a novel form of blood-based ca... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 1
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Advances In the Delayed-Onset of Type 1 Diabetes: Strategies to Improve Awareness and Care for the Practicing Clinician - Part 3
Target Audience
This activity is designed to meet the educational needs of Pediatric and Adult Endocrinologists, Pediatricians, Primary Care Providers, and Endocrine Nurses.
Program Overview
During this program, experts will present overviews of the importance of early screening and staging for type 1 diabetes (T1D), strategies and practical pearls for screening and follow-up, how to intervene early with disease-modifying therapies to delay progression to clinical T1D, as well as ongoing ... |
|
|
Mastering Treatment-Naive nAMD
In this Master Class case, Dr. Priya Vakharia discusses the management of a 72-year-old White man with treatment-naive neovascular age-related macular degeneration. |
|
|
Mastering Suboptimal Treatment Response in nAMD
In this Master Class case, Dr. David Eichenbaum discusses the management of a 69-year-old White man with neovascular age-related macular degeneration who receives a suboptimal treatment response to initial anti-vascular epithelial growth factor therapy. |
|
|
Mastering Treatment-Refractory nAMD
In this Master Class case, Dr. Michael Singer discusses the management of an 82-year-old Hispanic man with treatment-refractory neovascular age-related macular degeneration. |
|
|
Mastering Treatment-Naive DME
In this Master Class case, Dr. Mark R. Barakat discusses the management of a 76-year-old White man with treatment-naive diabetic macular edema. |
|
|
Mastering Suboptimal Treatment Response in DME
In this Master Class case, Dr. W. Lloyd Clark discusses the management of a 75-year-old Black woman with diabetic macular edema who has a suboptimal treatment response to initial anti-vascular epithelial growth factor therapy. |
|
|
Mastering Treatment-Refractory DME
In this Master Class case, Dr. Diana Do discusses the management of a 58-year-old White woman with treatment-refractory diabetic macular edema. |
|
|
Recognizing and Confirming Potential ATTR in Your Patients
Target Audience
This activity is designed to meet the educational needs of physicians, allied health practitioners, and students interested in complex cardiovascular and thoracic conditions and those who care for patients with ATTR.
Program Overview
This activity will cover early diagnosis and intervention for transthyretin amyloidosis (ATTR), which is critical, yet does not occur, typically as a consequence of the rarity and heterogeneity of the disease and limited awareness on the part ... |
|
|
Navigating the Evolving Standards of Newly Diagnosed Multiple Myeloma Treatment: Exploring the Evidence on New Combination Strategies
ACTIVITY DESCRIPTION
The goal of treatment for newly diagnosed multiple myeloma (NDMM) patients is achieving the deepest possible remission, which typically involves aiming for minimal residual disease negativity. Frontline therapy for NDMM is evolving to include novel induction regimens with anti-CD38 antibodies, which have been shown to yield improved depth of response after induction. These new frontline treatments vary in induction regimen composition and use of transplant, consolidation,... |
|
|
ASCVD Clinical Research Updates Targeting Residual Inflammation in Patients with ASCVD and CKD
Emerging evidence and scientific advancements are revealing pathophysiologic mechanisms correlated with systemic inflammation and the development of atherosclerotic cardiovascular disease (ASCVD). Patients with chronic kidney disease (CKD) are at high risk for developing ASCVD. Novel anti-inflammatory therapies are showing efficacy at reducing inflammation and development of ASCVD, and are adding to the treatment options beyond the usual lipid-lowering agents. As new clinical evidence and tar... |
|
|
Geographic Atrophy Secondary to Age-Related Macular Degeneration: Innovative Therapies for Sight Revival
Multimodal imaging is key for the early detection and monitoring of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Optical coherence tomography has recently been recommended by an international consensus to be the primary imaging method for the detection of atrophy in eyes. Once diagnosed, timely therapeutic intervention should be initiated with recently FDA-approved therapies that target components of the complement cascade. When optimally integrated into persona... |
|
|
Improving the Diagnosis and Management of Pulmonary Progressive Fibrosis (PPF): A Focus on Systemic Sclerosis Interstitial Lung Disease (SSc-ILD) and Idiopathic Pulmonary Fibrosis (IPF)
Target Audience
This activity is designed to meet the educational needs of rheumatologists, pulmonologists, and advanced practice providers.
Program Overview
This activity features an interactive case-based format where you can review questions to determine best practices in diagnosing and managing PPF, SSc-ILD, and IPF. This session offers real-life examples to help differentiate diseases within the Pulmonary Progressive Fibrosis (PPF) group, such as Idiopathic Pulmonary Fibrosis (IPF) a... |
|
|
Bunion-Like Toes and Tumor Like Swellings " Recognize FOP and Improve Patient Outcomes in the Era of Disease Specific Therapy
Target Audience
This activity is designed to meet the educational needs of healthcare providers in pediatrics, primary care, oncology, surgery, radiology, acute care, emergency medicine, rheumatology, and infectious disease.
Program Overview
Bunion-like toes present at birth and tumor-like swellings in a young child are diagnostic signs of fibrodysplasia ossificans progressive (FOP), a disease with recent advances made in therapy. Upon completion of the course, learners should be able to ... |
|
|
Podcast: Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
With the complex and rapidly evolving treatment landscape of multiple myeloma, it is vital that clinicians not only understand factors for informing selection of current and emerging combination and sequential therapeutic strategies, but also employ interdisciplinary strategies for reducing disparities in relapsed/refractory multiple myeloma care. The development of novel therapeutic options has significantly improved treatment outcomes for patients with relapsed/refractor... |
|
|
Defining the therapeutic algorithm in patients with HR positive breast cancer - United States
Target Audience
The initiative will target oncology clinicians in the US, Germany, Spain, Italy, and France, and specifically those actively involved in the treatment of breast cancer
Learning Objectives
Upon completion of this activity, participants should be better able to:
Assess the efficacy of new target therapy options in the management of patients with HR + early and metastatic BC with and implications for team-based and shared decision-making globall
Apply the most recent evid... |
|
|
Bridging the Health Gaps in Hereditary Angioedema: Demystifying Disparities, Enhancing Quality of Life, and Implementing Effective Prophylactic Solutions
Hereditary angioedema (HAE) is a rare, life-threatening disorder characterized by recurrent, unpredictable episodes of bradykinin-induced swelling. In this presentation, Dr. Marc Reidl, Clinical Director of the US Hereditary Angioedema Association (HAEA) Angioedema Center, reviews multiple underrecognized factors that contribute to health disparities among patients with HAE, including delays in diagnosis and multifaceted differences among racial and ethnic groups, socioeconomic status levels, ... |
|
|
Ace the Case: A 15-Year-Old Girl With a Remote History of Rash While Taking Amoxicillin
This educational activity will utilize a case study to discuss a 15-year-old girl with a remote history of a rash while taking amoxicillin. |
|
|
Ace the Case: A 77-Year-Old Man With Chronic Heartburn and Persistent Abdominal Pain
This educational activity will utilize a case study to discuss a 77-year-old man who presents with a history of chronic heartburn and 3 months of persistent abdominal pain. |
|
|
Ace the Case: A 38-Year-Old Man With Resistant Hypertension
This educational activity will utilize a case study to discuss a 38-year-old man with resistant hypertension. |
|
|
Ace the Case: A 47-Year-Old Woman With Lethargy, Confusion, and Muscle Weakness
This educational activity will utilize a case study to discuss a 47-year-old woman with lethargy, confusion, and muscle weakness. |
|
|
Treating SCLC in the Relapsed/Refractory Setting: Giving Patients a Voice About Second-Line Therapy
SCLC is aggressive in nature with a high recurrence rate following initial treatment and a propensity to become resistant to conventional therapies. Early detection is critical, but many patients are diagnosed at an advanced stage where prognosis is poor. Progress in the second-line setting offers new hope for improving patient outcomes, but the rapid pace at which these advances are occurring present challenges for effectively integrating novel therapies into patient care. In fact, research s... |
|
|
Chronic Rhinosinusitis with Nasal Polyps Navigating New Pathways to Better Patient Outcomes
Chronic inflammatory diseases of the upper and lower airways, especially CRSwNP and asthma, have been tied to significant risks and burdens for affected patients and frequently require close coordinated multidisciplinary care. Targeted agents designed to interrupt inflammatory cytokine signaling have been examined in clinical trials and evidence suggests these options can provide a range of benefits in patients with CRSwNP and related comorbidities. During this interactive activity, expert fac... |
|
|
Inherited Retinal Diseases: Navigating the Future of Diagnostics and Emerging Therapies
The differential diagnosis and workup of a suspected inherited retinal disease (IRD) can be challenging, requiring the expertise of the multidisciplinary healthcare team. Guidelines released in 2022 by the American Academy of Ophthalmology provide recommendations and clinical genetic assessments for patients with IRDs. Genetic counseling is essential to help patients understand the genetic test results, their implications for prognosis, family planning, and therapeutic decisions. Genetic testi... |
|
|
Patient Point of View: PDE4 Inhibitors for the Treatment of Adult Plaque Psoriasis
Psoriasis is a chronic, immune-mediated inflammatory skin disorder that significantly impacts affected individuals’ quality of life. The most common subtype is plaque psoriasis, characterized by erythematous to violaceous plaques covered with scales. Due to the substantial symptom burden of plaque psoriasis and challenges surrounding medication tolerability and adherence, innovative treatment options are needed. Phosphodiesterase-4 (PDE4) inhibitors, which play a key role in the inflammatory... |
|
|
Overcoming the Hurdles: Advances in the Management of Hemophilia
In this fast-moving, 1-hour accredited activity, Craig Kessler, MD, and Guy Young, MD, share their thoughts and experience with clotting factor concentrates, recombinant factor, factor VIII mimetics, rebalancing agents, and gene therapies. The safety and efficacy of late-phase investigational products are also discussed as these agents have the potential to address unmet needs and further transform patient care. |
|
|
Cushing’s Syndrome Treatment Research Highlights: ENDO 2024
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in endorcrinology, radiology, neurosurgery, and general practice. Other members of the care team may also participate.
Program Overview
This 30-minute CME program highlights the latest clinical research about Cushing’s syndrome and Cushing’ disease.
Learning Objectives
After participating in the activity, learners should be better able to:
Describe the latest research being ... |
|
|
Extending Dosing Intervals in Retinal Disease: Patient Perspectives and Clinical Insights to Guide Your Practice
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are increasingly prevalent retinal diseases that pose significant challenges in ophthalmic care. While anti-vascular endothelial growth factor (VEGF) therapies have greatly improved visual outcomes for patients with these conditions, real-world data indicate that many patients receive suboptimal treatment and monitoring, resulting in poorer visual outcomes. Newer therapeutic options have been developed to exte... |
|
|
Nutraceuticals for Dry Eye: Dispelling the Dogma and Embracing the Data
Dry eye disease is a common yet frequently overlooked condition that significantly affects quality of life. Despite an estimated global prevalence of up to 50%, DED is often underdiagnosed and inadequately managed. To limit the burden of DED, it is crucial for clinicians to be adept at recognizing risk factors and making accurate diagnoses. In addition, as treatment options expand to include clinically proven nutraceuticals, it is imperative that clinicians stay abreast of the latest clinical ... |
|
|
Patient‐Centered GA Care: A Synergistic Approach to Optimize Management
The recent FDA approval of 2 novel therapies for the management of patients with geographic atrophy (GA) secondary to age-related macular degeneration has further reenforced the necessity for early GA diagnosis to limit progression. Advances in imaging technologies now provide tools for better detection and characterization of GA, along with biomarkers to monitor progression over time. Optometrists, as front-line eye healthcare providers, play a critical role in the timely diagnosis, managemen... |
|
|
Can You Diagnose This Patient With Impaired Balance and Paresthesia?
When your patient presents with symptoms such as impaired balance and paresthesia, what might you first suspect and can you reach the right diagnosis? Put your diagnostic skills to the test! In just 15 minutes, navigate through real-world cases and upon completion, hear faculty insights on the implications of your decisions along with rationales for appropriate next steps to aid in making a final diagnosis, as well as evidence-based treatment strategies. Apply the latest scientific evidence in... |
|
|
Neuropsychiatric Complications of Parkinson’s Disease Psychosis
Target Audience
This activity is designed to meet the educational needs of Neurologists, neurology NPs, neurology PAs.
Program Overview
Join us for a dynamic one-hour CME activity on Parkinson’s Disease Psychosis (PDP) with top experts Mark F. Lew, MD, and Jennifer Hui, MD. Unlock the latest best practices for diagnosing PDP and implementing cutting-edge therapies. The session kicks off with a deep dive into Parkinson’s Disease, covering its prevalence, motor and nonmotor symptoms, an... |
|
|
The Pharmacist’s Role in Individualizing Therapy for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, immune-mediated neurologic disorder that can lead to severe disability if left untreated. Early and accurate diagnosis for CIDP is challenging and usually delayed, but early initiation and maintenance of immunoglobulin-based treatment is crucial. Due to the heterogenous nature of the disease, treatment strategies need to be individualized, and pharmacists play an integral role through ongoing patient communications/education, ... |
|
|
Cushing’s Syndrome Treatment Research Highlights
This 30-minute CME program highlights the latest clinical research about Cushing’s syndrome and Cushing’ disease.
Cushing’s syndrome is rare endocrine disorder characterized by chronic hypercortisolism. It is often due to a pituitary adenoma producing excessive ACTH leading to hypercortisolism. Symptoms can range from mild to extensive.
This CME program, hosted by Maria Fleseriu, MD, FACE, Professor of Medicine and Neurological Surgery, Director of the Pituitary Center at Oregon He... |
|
|
HER3 in NSCLC " Navigating New Frontiers in Targeted Therapy
In patients with non-small cell lung cancer (NSCLC), human epidermal growth factor receptor 3 (HER3) is associated with both advanced disease and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)"directed therapies. Although there are therapeutic options targeting EGFR (HER1) and HER2, the potential of HER3 as an anti-cancer target has been largely overlooked. Overexpression of HER3 in most patients with NSCLC positions it as an appealing therapeutic targ... |
|
|
Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Collecting peripheral blood stem cells (PBSCs) is an essential component of ASCT, and the collection of sufficient autologous PBSCs relies on the successful mobilization of hematopoietic stem cells from the bone marrow niche i... |
|
|
Toxicity Management and Symptom Control in Advanced RCC: Playbook Update
STATEMENT OF NEED
Each year, more than 430,000 cases of kidney cancer are diagnosed worldwide. Renal cell carcinoma (RCC), which includes clear cell, papillary, and chromophobe subtypes, is the most common form of kidney cancer. In recent years, the rise of immunotherapy and targeted therapy has contributed to a revolution in the treatment of RCC, with several novel agents and combinations granted approval. While these treatments demonstrate superior efficacy compared with previous standard... |
|
|
Point-of-Care OB/Gyn Ultrasound - Blended Course
The Point-of-Care OB/GYN Ultrasound Blended Course, specifically designed for physicians and mid-level/advanced practice providers, will provide a strong foundation to utilize ultrasound to visualize maternal and fetal anatomy to enhance accurate and timely clinical decisions at the bedside.
Begin with the self-paced online course: Taught by leading OB/GYN ultrasound experts, the comprehensive online course covers point-of-care gynecological sonoanatomy & scan technique, sonographic app... |
|
|
THE MICRONUTRIENTS: Vitamin A & Carotenoids
Pharmacists are often sought after for guidance on choosing and using nutritional supplements. However, many current pharmacists did not receive comprehensive education on vitamins and minerals during their academic training. Even those who did may not be up to date on recent research that has broadened our knowledge of how deficiencies and excesses of certain micronutrients can impact health, as well as how these nutrients may interact negatively with specific medications.
For anyone pass... |
|
|
THE MICRONUTRIENTS: Survey of 13 Vitamins, Deficiencies, Supplements, and Interactions (Home Study Bundle)
Pharmacists are often sought after for guidance on choosing and using nutritional supplements. However, many current pharmacists did not receive comprehensive education on vitamins and minerals during their academic training. Even those who did may not be up to date on recent research that has broadened our knowledge of how deficiencies and excesses of certain micronutrients can impact health, as well as how these nutrients may interact negatively with specific medications.
For anyone passi... |
|
|
The Retina Radar With Dr. Arshad Khanani on DR, GA, New Mechanisms, and Noninvasive Treatments
Retinal diseases are a leading cause of global vision impairment, driven by an increasing prevalence and the need for more effective treatment. Although clinical trials have shown promising results for various therapies, real-world application often yields less impressive outcomes due to factors like under-treatment and patient non-adherence. New and emerging therapies, particularly for conditions like diabetic macular edema (DME), diabetic retinopathy, and geographic atrophy (GA) secondary to... |
|
|
Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.
Target Audience
The primary target audience for this activity are Academic and community-based physicians and team members, including hematologists, hematologic oncologists, medical oncologists, oncology nurses, NPs, PAs, and hematology-oncology pharmacists.
Statement of Need/Program Overview
Bispecific antibodies are relatively new agents in the treatment of multiple myeloma (MM). Because of this, many oncology clinicians are unfamiliar with their mechanism of action and the adverse even... |
|
|
New Guidelines, Emerging Treatments, and Unexpected Patients: Understanding the Challenges of PAH
Target Audience
This activity is designed for nurse practitioners, nurses, and physician assistants who manage patients with or at risk for PAH.
Program Overview
It is a deadly disease and there’s still no cure, but with treatment, survival for patients with pulmonary arterial hypertension (PAH) can be significantly extended. Although rare, nurse practitioners are likely to encounter this cardiopulmonary disorder throughout their careers, and need to be familiar with the multiple dru... |
|
|
GA and Advances in Imaging and Surgery: State-of-the-Art Management
The continued evolution of diagnostic, therapeutic, and surgical algorithms for the management of patients with retinal diseases offer the potential for enhancing visual, anatomical, and quality-of-life outcomes in these patients. Recognition, understanding, and application of these evidence-based advances are imperative to enhance treatment outcomes and patient satisfaction. During Part 2 of this 2-part educational activity, updates in geographic atrophy will be discussed, along with advances... |
|
|
nAMD, Diabetic Eye Disease, and RVO: State-of-the-Art Management
The continued evolution of diagnostic, therapeutic, and surgical algorithms for the management of patients with retinal diseases offer the potential for enhancing visual, anatomical, and quality-of-life outcomes in these patients. Recognition, understanding, and application of these evidence-based advances are imperative to enhance treatment outcomes and patient satisfaction. During Part 1 of this 2-part educational activity, updates in state-of-the-art management strategies for neovascular ag... |
|